文章：

无贝伐珠单抗腹腔化疗对比含贝伐珠单抗静脉化疗作为晚期卵巢癌一线辅助治疗

Intraperitoneal Chemotherapy without Bevacizumab versus Intravenous Chemotherapy with Bevacizumab as the Frontline Adjuvant Therapy in Advanced Ovarian Cancer

原文发布日期：3 October 2024

DOI: 10.3390/cancers16193382

类型: Article

开放获取: 是

英文摘要：

Objectives:To compare the clinical outcomes of intravenous carboplatin/paclitaxel chemotherapy plus bevacizumab versus intraperitoneal cisplatin/paclitaxel chemotherapy without bevacizumab as the frontline treatment in women with advanced ovarian, fallopian tube and primary peritoneal cancer.Methods:Between November 2012 and January 2024, medical records of all consecutive women with stage II~IV cancer treated with either frontline adjuvant intraperitoneal cisplatin/paclitaxel without bevacizumab (IP group), intravenous carboplatin/paclitaxel without bevacizumab (IV group) or intravenous carboplatin/paclitaxel with bevacizumab (IVB group) at a tertiary referral center were reviewed.Results:A total of 143 women (IP group, n = 57; IVB group, n = 23; IV group, n = 63) were reviewed. The IP group had greater progression-free survival compared to the IVB group (49.1 months, 95% confidence interval [CI] = 27.8 months to infinity, versus 11.9 months, 95% CI = 11.2 to 16.2 months; adjusted hazard ratio [HR] = 0.45, 95% CI = 0.24 to 0.87,p= 0.017). Additionally, the IP group also had a higher overall survival compared to the IVB group (not reached, 95% CI = 55.6 months to infinity, versus 38.9 months, 95% CI = 21.9 months to infinity; adjusted HR = 0.34, 95% CI = 0.15 to 0.79,p= 0.012).Conclusions:Intraperitoneal cisplatin/paclitaxel chemotherapy without bevacizumab seems to offer a survival advantage when compared with intravenous carboplatin/paclitaxel with bevacizumab in the frontline treatment of women with advanced ovarian cancer.

摘要翻译： 

目的：比较静脉注射卡铂/紫杉醇联合贝伐珠单抗与腹腔注射顺铂/紫杉醇不联合贝伐珠单抗作为晚期卵巢癌、输卵管癌及原发性腹膜癌患者一线治疗的临床疗效。 方法：回顾性分析2012年11月至2024年1月期间，在某三级转诊中心连续接受一线辅助治疗的II~IV期癌症患者的医疗记录。治疗方案包括：未联合贝伐珠单抗的腹腔注射顺铂/紫杉醇（IP组）、未联合贝伐珠单抗的静脉注射卡铂/紫杉醇（IV组）以及联合贝伐珠单抗的静脉注射卡铂/紫杉醇（IVB组）。 结果：共纳入143例患者（IP组57例，IVB组23例，IV组63例）。与IVB组相比，IP组显示出更长的无进展生存期（49.1个月，95%置信区间[CI] = 27.8个月至无穷大，对比11.9个月，95% CI = 11.2至16.2个月；调整后风险比[HR] = 0.45，95% CI = 0.24至0.87，p = 0.017）。此外，IP组的总生存期也高于IVB组（未达到，95% CI = 55.6个月至无穷大，对比38.9个月，95% CI = 21.9个月至无穷大；调整后HR = 0.34，95% CI = 0.15至0.79，p = 0.012）。 结论：在晚期卵巢癌患者的一线治疗中，未联合贝伐珠单抗的腹腔注射顺铂/紫杉醇化疗方案相较于联合贝伐珠单抗的静脉注射卡铂/紫杉醇方案，可能具有生存优势。

原文链接：

Intraperitoneal Chemotherapy without Bevacizumab versus Intravenous Chemotherapy with Bevacizumab as the Frontline Adjuvant Therapy in Advanced Ovarian Cancer